Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Controlling glycaemic variables with pioglitazone prior to and during therapy with peginterferon alfa-2a + ribavirin does not improve early virological response in patients with chronic genotype 1 hepatitis C

Next Previous
Trial Profile

Controlling glycaemic variables with pioglitazone prior to and during therapy with peginterferon alfa-2a + ribavirin does not improve early virological response in patients with chronic genotype 1 hepatitis C

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; Insulin resistance
  • Focus Therapeutic Use
  • Acronyms SENSITIZE

Most Recent Events

  • 15 Feb 2012 Results published in the Hepatology.
  • 08 Nov 2011 Results including 72 week data presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 04 Nov 2011 Primary endpoint 'Early-virological-response-rate' has not been met (3063700) as reported by result presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top